esketamine (spravato) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

  • Now
Esketamine is an S(+)-enantiomer of ketamine. It is a nonselective, noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptor. A nasal spray, containing esketamine, was approved in 2019 for the treatment of treatment-resistant depression in adults, in conjunction with an oral antidepressant, and is marketed under tradename SPARAVATO. Esketamine is a schedule III drug product in the USA.   NCATS

More Chemistry

Drug Pricing (per unit)

United States

$221.8600 - $291.5300
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

am-101 | esketamine | esketamine hcl | esketamine hydrochloride | programmed cell death 5 protein, rat | (s)-(+)-ketamine hydrochloride


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue